BRIDGEWATER, N.J., March 21, 2017 /PRNewswire/ -- Sanofi
Consumer Healthcare – the makers of new
Xyzal® Allergy 24HR, which is now available on
retail shelves nationwide – revealed today the results of a social
experiment in which 160 participants (80 allergy sufferers and 80
non-sufferers) wore a wearable device for 30 days to track their
sleep and activity. The first-of-its-kind experiment found allergy
symptoms can impact various elements of sufferers' lives, including
both the quality of their sleep and their daytime activities. Xyzal
is partnering with renowned allergist Dr. Neeta Ogden to encourage allergy sufferers to
Wise Up about the importance of managing their allergies
this spring, so they can have a better night's sleep and Rise
Up in the morning to take on the day.
Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/8029451-sanofi-xyzal-allergy-social-experiment-wise-up-rise-up/
"Many allergy sufferers have gotten so used to their symptoms
that they don't even realize how significantly they may be
impacting their day-to-day lives, including everything from their
sleep at night to their productivity during the day. But the
results of this social experiment should serve as a wake-up
call," said Dr. Ogden. "If your allergy symptoms aren't
under control, it's time to educate yourself about both your
triggers and your treatment options, so you can find relief that
doesn't rest and enjoy the spring season."
Participants in the experiment also completed a daily survey to
track perceptions of their allergy symptoms (for the 80 allergy
sufferers), sleep patterns and activities, as a way to provide
additional context for the wearable device data. Specific findings
from the social experiment include the following:
- Allergy sufferers had a harder time falling asleep and
staying asleep than people without allergies.
- Allergy symptoms were the top factor that negatively impacted
the sleep of these allergy sufferers—even more so than stress,
discomfort, temperature or work.
- In fact, the experiment found that an allergy sufferer's sleep
could be disrupted nearly 4 times more than that of a person
without allergies.
- Allergy sufferers were less rested and less physically
active during the day than people without allergies.
- For example, allergy sufferers traveled an average of only 3.16
miles a day while active, whereas people without allergies traveled
3.35 miles. That could translate to 69 fewer miles per year—the
distance of approximately two and a half marathons.
About Xyzal
Xyzal is an oral antihistamine that is now available
over-the-counter (OTC) at full prescription strength. No
other 24-hour antihistamine delivers better relief of your worst
allergy symptoms than new Xyzal Allergy 24HR. It offers continuous,
maximum strength relief of sneezing, runny nose, itchy, watery eyes
and itchy nose or throat, all in a single daily dose. In fact,
Xyzal is as effective at hour 24 as it is at hour 1, providing all
night and all day allergy relief that can help patients get a
better night's sleep and a better day's productivity. Xyzal has
been available as a prescription product for nearly a decade and is
now available OTC in two formulations – 5 mg tablets for ages 6
years and older, as well as a 0.5 mg/mL oral solution for ages 2
years and older. For more information, visit
www.Xyzal.com.
About the Social Experiment
This social experiment was sponsored by Sanofi Consumer Healthcare
and conducted by Russell Research. It used wearable devices to
assess the sleep patterns and activities of 160 participants (80
allergy sufferers and 80 non-sufferers) for 30 consecutive days
between October and December 2016.
For the purposes of the experiment, allergy sufferers are defined
as those who suffer from moderate or severe indoor and outdoor
allergies in the fall or year round, and who take allergy
medication 2 days per week or less.
For more information about the impact of allergy symptoms on
people's lives and the importance of allergy management, visit
www.Xyzal.com or find us on Twitter, Facebook, and Instagram.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs.
Sanofi is organized into five global business units: Diabetes and
Cardiovascular, General Medicines and Emerging Markets, Sanofi
Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed
in Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).
Contacts:
Media
Relations
Heather
Guzzi
Tel. : (908)
981-3164
heather.guzzi@sanofi.com
|
Media
Relations
Ashleigh
Koss
Tel. : (908)
981-8745
ashleigh.koss@sanofi.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sanofi-announces-results-of-first-of-its-kind-social-experiment-revealing-real-life-impact-of-symptoms-on-allergy-sufferers-in-the-us-300426248.html
SOURCE Sanofi